Rate dependency' in the discipline of behavioral pharmacology describes a phenomenon wherein the effect of a drug on the rate of a behavior varies systematically as a function of the baseline, predrug rate of that behavior. Historically, rate-dependency studies have compared drug effects on different baseline rates of behavior maintained either by different schedules of reinforcement or during sequential segments of a fixed-interval schedule. The current experiment generated different baseline rates of behavior by altering frequency of electrical stimulation in an intracranial self-stimulation assay. Amphetamine and 10 other monoamine releasers were analyzed for their ability to produce rate-dependent effects in this assay. There were three main findings. First, all compounds produced rate-dependent effects at some dose. Second, one parameter of rate-dependency plots (peak Y-intercept of the regression line) correlated with in-vitro neurochemical data on selectivity of these compounds to release dopamine versus serotonin (P < 0.025, R 2 = 0.50). Lastly, a correlation between peak Y-intercept and breakpoints under a progressive-ratio procedure in nonhuman primates was also significant (P < 0.05, R 2 = 0.64). Overall, these results extend the rate-dependent effects of monoamine releasers to behavior maintained under intracranial self-stimulation and suggest that, at least for monoamine releasers, the Y-intercept parameter of rate-dependency plots might be a useful metric of drug reward and predictor of drug selfadministration measures of drug reinforcement.
Introduction
'Rate dependency' in behavioral pharmacology describes a phenomenon in which the effect of a drug on the rate of a behavior varies systematically as a function of the baseline, predrug rate of that behavior (Dews, 1958 (Dews, , 1981 Sanger and Blackman, 1976) . Fixed-interval (FI) schedules of reinforcement have played a key role in research on rate-dependent drug effects, because these schedules often engender a wide range of response rates during successive segments of the interval and thereby provide a useful baseline of behavior for assessment of drug effects across baseline rates (Ferster and Skinner, 1957; Sanger and Blackman, 1976) . Rate-dependent effects of a given drug dose under FI schedules are typically manifested as some degree of increase in low rates of behavior coupled with smaller increases or decreases in higher rates of behavior, and this relationship is often displayed as a negatively sloped line on a graph that plots baseline rate on the horizontal axis (usually expressed as 'log baseline rate') as a function of rate after drug administration on the vertical axis (usually expressed as 'log% baseline rate') (Dews, 1964; Kelleher and Morse, 1968; McMillan, 1973; Sanger and Blackman, 1976) . Linear regression of the resulting plot can then yield parameters such as -slope and Y-intercept, and these parameters can be used for quantitative comparison of rate dependency across doses of a given drug, across drugs, or across experimental conditions. For example, effects of amphetamine on operant responding under FI schedules are often rate dependent, and the degree of rate dependency (as indicated by the slope of the ratedependency regression) typically increases with dose and is more prominent with unpunished than with punished responding (McMillan, 1973; Ksir, 1981) . Baseline rate is only one of many variables that may influence drug effects on behavior, and other important variables include the schedule of reinforcement and the maintaining event (Sanger and Blackman, 1976; McKearney, 1981) . Nonetheless, consideration of rate dependence has advanced behavioral pharmacology by promoting analysis of drug effects in terms of quantifiable behavioral variables (Dews, 1981) .
Intracranial self-stimulation (ICSS) is the general label for a family of operant conditioning procedures that use electrical brain stimulation as the reinforcing stimulus (Olds and Milner, 1954; Stellar and Stellar, 1985; Shizgal and Murry, 1989; Lewis, 1993) . Relative to other commonly used reinforcing stimuli, such as food delivery or drug injections, electrical stimulation is distinguished by the speed of its delivery, the brevity of its effects, and the precise degree of control over its magnitude. For example, stimulus parameters commonly used in ICSS studies employ stimulus delivery within ms of a response, stimulus durations of 0.5 s or less, and stimulus magnitudes that vary across frequency or amplitude increments as low as 0.05 log units. These characteristics have been exploited to develop ICSS procedures that, like FI schedules with more conventional reinforcers, can engender a wide range of baseline behavioral rates during relatively short (10 min) experimental sessions (Carlezon and Chartoff, 2007; Vlachou and Markou, 2011) . However, data from ICSS experiments have generally not been viewed through the lens of rate-dependency analysis. Rather, the most common approaches to data analysis focus on low rates of responding maintained by low stimulus magnitudes to determine 'thresholds' of stimulation required to maintain responding (Miliaressis et al., 1986) . Drug-induced changes in threshold are often interpreted as evidence of 'reward' (if a drug increases low rates of responding and decreases threshold) or 'anhedonia' (if a drug decreases low to intermediate rates of responding and increases threshold); moreover, druginduced changes in low rates of responding are often distinguished from drug effects on high rates of responding, which are often interpreted as evidence of 'motoric' or 'performance' effects (Stellar and Rice, 1989; Lewis, 1993; Carlezon and Chartoff, 2007; Vlachou and Markou, 2011) . However, the contribution of rate dependency to drug effects in other behavioral procedures suggests that rate dependency might also contribute to drug effects on ICSS, such that drug-induced changes in low and high rates of ICSS might reflect a common rate-dependent process rather than distinct effects on distinct processes such as sensitivity to brain stimulation and motor capacity for performing the response.
One application of ICSS has been to assess rewarding drug effects that may contribute to abuse potential (Kornetsky and Esposito, 1979; Vlachou and Markou, 2011) , and we recently suggested that this application of ICSS might benefit from strategies for data analysis that integrate both rate-increasing and rate-decreasing drug effects (Bauer et al., 2013) . Rate dependency provides both a conceptual framework and analytic approach for achieving that integration. Accordingly, the aim of the present report was to apply rate-dependency analysis to a previously published ICSS data set for 11 monoamine releasers (Bauer et al., 2013) . The drugs span a more than 8000-fold range of pharmacological selectivity for releasing dopamine/norepinephrine versus serotonin, and include relatively dopamine/norepinephrine-selective releasers (e.g. PAL-353 and amphetamine), the serotoninselective releaser fenfluramine, and a series of releasers with graded selectivities between these extremes. Ratedependency plots were generated from mean ICSS data for each dose of each drug as described previously with morphine (Altarifi and Negus, 2011) , and these plots were then submitted to regression analysis to compare their -slopes and Y-intercepts. Parameters of ratedependency plots were correlated with dose within each drug, with pharmacological selectivity across drugs, and with data from nonhuman primate drug self-administration assays of abuse-related effects.
Methods

Subjects
Methodological details of this study were reported previously (Bauer et al., 2013) . Briefly, 38 adult male Sprague Dawley rats (Harlan, Frederick, Maryland, USA) were equipped with stimulating electrodes that targeted the left medial forebrain bundle at the level of the lateral hypothalamus. All rats had free access to food and water and were housed individually on a 12 h light-dark cycle (lights on from 06:00-18:00 h) in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. Animal maintenance accorded with the National Institutes of Health guidelines on care and use of animal subjects in research (National Research Council, 2011) . Experimental protocols were approved by the Virginia Commonwealth University Institutional Animal Care and Use Committee.
Apparatus
Operant chambers consisted of sound-attenuating boxes containing modular acrylic and metal test chambers (Bauer et al., 2013) . Each chamber had a response lever, three stimulus lights (red, yellow, and green) centered above the response lever, a house light, and an ICSS stimulator (Med Associates, St. Albans, Vermont, USA). Bipolar cables routed through a swivel commutator connected the stimulator to the electrode (Model SL2C; Plastics One, Roanoke, Virginia, USA). Med-PC IV computer software controlled all programming parameters and data collection (Med Associates).
Training
Animals were trained to respond on an FR 1 schedule for the delivery of a 0.5-s train of square-wave cathodal pulses (0.1 ms/pulse). Under the terminal schedule, daily experimental sessions consisted of multiple 10-min components, and each component consisted of 10 1-min trials. The stimulation frequency was 158 Hz (2.2 log Hz) for the first trial and decreased 0.05 log units during each of the subsequent nine trials to a final frequency of 56 Hz (1.75 log Hz). Stimulation intensity was individually manipulated to identify an intensity that maintained greater than half-maximal responding for five of the 10 trials. Each trial began with a 10-s time-out period, during which responding had no scheduled consequences, and five noncontingent stimulations at the designated frequency were delivered at 1-s intervals during the last 5 s of the time-out. During the remaining 50 s of each trial, responding produced both intracranial stimulation at the Rate dependence of releasers in ICSS Bauer et al. 449 designated frequency and illumination of the lever lights under the FR 1 schedule as described above. Thus, each component generated 10 different response rates maintained by 10 different brain-stimulation frequencies.
Training continued until mean frequency-rate curves were not significantly different over 3 days of training, as indicated by lack of a significant effect of 'day' in a twoway analysis of variance with frequency and day as the two variables (see the Data analysis section).
Testing
Test sessions consisted of three consecutive 'baseline' components followed first by a 20-min treatment period and then by three consecutive 'test' components. A single dose of a test drug or drug mixture was administered at the beginning of the treatment period, immediately after the baseline components and before the test components. All test drugs are listed in Table 1 in the order of their invitro selectivities for promoting release of dopamine versus serotonin (for all drugs, selectivities to release dopamine and norepinephrine were similar; see Rothman et al., 2001 Rothman et al., , 2002 Rothman et al., , 2005 Wee et al., 2005; Wang and Woolverton, 2007) . Also, tested were mixtures of the dopamine-selective releaser PAL-353 and the serotoninselective releaser fenfluramine in proportions of 1 : 1, 1 : 3, and 1 : 10 PAL-353 : fenfluramine. These proportions were based on the relative potencies of PAL-353 and fenfluramine to alter ICSS and were intended to permit assessment of PAL-353 in combination with relatively low, intermediate, and high proportions of fenfluramine. Test sessions were usually conducted on Tuesdays and Fridays, and three-component training sessions were conducted on all other weekdays. Each drug or drug mixture was tested in a group of 5-7 rats, such that all subjects in the group received all doses, and the order of drug dose was varied across subjects using a Latin-square design. Any given rat was used to test two to three drugs. The order of drug testing was irregular across rats, and experiments with any one drug or drug mixture in a given rat were completed before progressing to another. Tests with different drugs in a given rat were separated by at least 1 week, and during this interdrug interval, a saline/ vehicle test session was conducted to assure that previous treatments did not alter ICSS measures. 
Data analysis
The primary dependent measure was the reinforcement rate in stimulations/trial. Raw reinforcement rates were normalized to the maximum control rate (MCR) for each subject on each day, wherein MCR was defined as the mean of the maximal rates observed during the second and third 'baseline' components for that day. Therefore, %MCR was equal to [response rate during a frequency trial)/(MCR)] Â 100. Mean±SEM MCRs were 58.6±1.3 stimulations per trial. ICSS rates, expressed as %MCR, for each frequency were averaged across (a) the second Note that peak values for the two rate-dependency plot parameters were sometimes obtained at different drug doses. Pharmacological selectivity of each drug to release dopamine versus serotonin is also shown. These values were generated from in-vitro synaptosome preparations taken from rat caudate nuclei (DA) or whole brain minus caudate and cerebellum (5HT) (references below). MDMA, 3,4-methylenedioxymethamphetamine. Wee et al. (2005) . e Wang and Woolverton (2007) . f Fenfluramine produced a positive slope. Therefore, 'peak' effect is lower than 2.0. and third baseline components and (b) all three test components, for each rat and then across rats, to yield curves relating brain-stimulation frequency to baseline and test ICSS rates for each experimental manipulation. These baseline and test data were then used to generate a rate-dependency plot in which the x-axis was log baseline rate and the y-axis was log [(test rate/baseline rate) Â 100]. Each rate-dependency plot consisted of 10 points for baseline and test rates maintained by each of the 10 different brain-stimulation frequencies. Each plot was then submitted to linear regression analysis to determine two parameters: (a) the slope (expressed as -slope so that increasingly steep slopes were expressed as increasingly positive numbers), and (b) Y-intercept (expressed as the intercept at x = 1, wherein the baseline rate equaled 10% MCR and log baseline rate equaled 1). The effects of a given dose of a given drug were considered to be 'rate dependent' if the 95% confidence limits of the slope did not include '0'. -Slope or Y-intercept parameters between doses of a given drug or between drugs were considered to be significantly different if 95% confidence limits did not overlap.
For each drug, the -slope and Y-intercept parameters were graphed as a function of drug dose (log scale). In addition, rate dependency across drugs was assessed by correlating peak -slope (for any dose of each drug) or peak Y-intercept (for any dose of each drug) with log in-vitro selectivity for release of dopamine versus serotonin. Data were analyzed by linear regression and a Pearson's correlation test. A P-value of less than 0.05 was determined to be significant for both the slope of the regression line and for the Pearson correlation test. All regression analyses were conducted using Prism 5.0c for Mac OS X (GraphPad Software, La Jolla, California, USA). Figure 1a shows the effects of a 30-fold range of amphetamine doses on ICSS frequency-rate curves [previously published; see Bauer et al. (2013) for time course, statistics, and other details]. Figure 1b shows the same data graphed as rate-dependency plots. Table 2 shows that all four doses of amphetamine produced ratedependent effects (insofar as 95% confidence limits of the rate-dependency slopes did not include '0'), but Note that slope values in Fig. 1c are graphed as ' -slope' to yield increasingly positive numbers for increasingly steep slopes. a Significant rate dependence as indicated by slope values that do not include '0' in the 95% confidence limits. b Significantly different from vehicle as indicated by nonoverlapping confidence intervals.
Results
Rate dependence of releasers in ICSS Bauer et al. 451 saline (vehicle) did not. Table 2 also shows that amphetamine produced dose-dependent increases in both -slope and Y-intercept parameters of the ratedependency plot. The dose dependency of amphetamine effects on these parameters of the rate-dependency plot is also shown in Fig. 1c . Figure 2d shows ratedependency plots for the effects of these three compounds, and linear regression analyses demonstrated that effects of PAL-353, PAL-287, and fenfluramine on ICSS were rate dependent (see below and Table 1 ). Figure 3 shows the -slope and Y-intercept data produced by the rate-dependency plots as a function of dose for all doses of PAL-353, PAL-287, fenfluramine, and six of the other releasers examined [amphetamine was previously shown in Fig. 1; (±)-3,4-methylenedioxymethamphetamine (MDMA) data (not shown) can be found in Table 1 ].
To further examine the relationship between rate dependency and pharmacological selectivity, the peak effects of each drug on -slope and Y-intercept parameters were correlated with in-vitro measures of pharmacological selectivity. Table 1 shows the peak effects of each drug on slope and Y-intercept parameters; note that, for some drugs, peak effects on these two parameters were produced by different doses. All drugs produced rate-dependent effects, but the profile of rate dependency varied across drugs. Specifically, all drugs except fenfluramine produced negatively sloped ratedependency plots, but the slopes and Y-intercepts varied across drugs. Fenfluramine produced a slope that was significantly different from zero [at a single intermediate dose (1.0 mg/kg) shown in Table 1 ], thus fulfilling our definition of rate dependency; however, the slope of this regression line was positive unlike the other drugs tested in this procedure. Figure 4 shows the correlation between these -slope and Y-intercept parameters and pharmacological selectivity [data for fenfluramine were excluded from the correlation because selectivity has not been precisely quantified due to very low potency to release dopamine (Rothman et al., 2001) ]. The correlation Rate dependence of releasers in ICSS Bauer et al. 453 between selectivity and -slope was not statistically significant (Pearson's r = 0.42, R 2 = 0.17, P = 0.23), but the correlation between pharmacological selectivity and Y-intercept achieved significance (Pearson's r = 0.71, R 2 = 0.50, P < 0.025).
The relationship between rate dependency and pharmacological selectivity was also examined with mixtures of the dopamine-selective releaser PAL-353 and the serotonin-selective releaser fenfluramine. Figure 5a -c shows effects of representative high doses of 1 : 1, 1 : 3, and 1 : 10 mixtures of PAL-353 and fenfluramine on ICSS frequency-rate curves [previously published, see Bauer et al. (2013) for other details]. Figure 5d shows the rate-dependency plots for these doses of these mixtures. Figure 6 shows the relationship between mixture dose and the rate-dependency plot parameters, -slope and Y-intercept, for each mixture. Table 3 shows the peak effects on slope and Y-intercept produced by any dose of each mixture. All three mixtures produced ratedependent effects at some dose insofar as 95% confidence limits of the rate-dependency slopes did not include '0'. Peak slopes of the rate-dependency plots were not different across mixtures; however, the 1 : 1 mixture produced the greatest increase in Y-intercept values, and mixtures with higher fenfluramine proportions produced progressively smaller increases in Y-intercept.
Discussion
Rate dependency and intracranial self-stimulation
Previous studies have identified rate-dependent effects of amphetamine or methamphetamine under a wide range of conditions (Sidman, 1956; Dews, 1958; Owen, 1960; Smith, 1964; Kelleher and Morse, 1968; Barrett, 1974; Harris et al., 1978) . The current study using an ICSS procedure in rats confirms and extends these earlier findings in three ways. First, amphetamine and methamphetamine predominately increased low ICSS rates maintained by low brain-stimulation frequencies while having little to no effect on high ICSS rates maintained by high brain-stimulation frequencies. Both drugs produced effects on ICSS that met the criterion for rate dependence (i.e. slope of the rate-dependency plot significantly different from '0'). Second, amphetamine and methamphetamine effects on parameters of the ratedependency plot were dose dependent, with increases in dose producing increases in both -slope and Y-intercept values. Amphetamine has previously been shown to produce dose-dependent changes in rate dependency under other conditions (Harris et al., 1978) . Lastly, the current study expanded assessment of rate dependency from the prototype amphetamines to nine other monoamine releasers that varied across a more than 8000-fold range in their pharmacological selectivity to release dopamine/norepinephrine versus serotonin, and to mixtures of dopamine-selective and a serotonin-selective Rate-dependency plot parameters as a function of pharmacological selectivity to release dopamine versus serotonin. Horizontal axes: pharmacological selectivity expressed as log (in-vitro potency to release serotoninÄin-vitro potency to release dopamine) as shown in Table 1 . Vertical axis (a): peak -slope for any dose of each drug as shown in Table 1 . Vertical axis (b): peak Y-intercept for any dose of each drug as shown in Table 1 . *Fenfluramine data were not included in the correlation because its in-vitro potency to release dopamine has not been precisely quantified.
releaser. At least one dose of each monoamine releaser and mixture produced rate-dependent effects, and this permitted correlation between rate-dependency plot parameters (-slope, Y-intercept) and pharmacological selectivity. Peak -slope values did not correlate with either pharmacological selectivity to release dopamine versus serotonin or with proportion of the dopamineselective versus serotonin-selective releasers in a mixture. By contrast, peak Y-intercept values did correlate significantly with pharmacological selectivity to release dopamine and were significantly higher for PAL-353/ fenfluramine mixtures that contained higher versus lower proportions of PAL-353. These findings suggest that ratedependent effects on ICSS may be shared across a wide range of monoamine releasers, and the vertical position of the rate-dependence plot (as defined by Y-intercept) may be an attribute of rate dependence that could be used to distinguish drugs.
Rate dependency in intracranial self-stimulation as an index of abuse-related effects
Both clinical (Brauer et al., 1996) and preclinical drug selfadministration studies (Wee et al., 2005; Wang and Woolverton, 2007) suggest that abuse-related effects of monoamine releasers vary as a function of pharmaco-logical selectivity to release dopamine versus serotonin.
In the present study, the peak Y-intercept parameter of rate-dependency plots in ICSS also correlated with pharmacological selectivity to release dopamine versus serotonin. Taken together, these findings suggest that peak Y-intercept of rate-dependent drug effects on ICSS in rats may serve as a predictor of other preclinical and clinical measures of abuse liability. To assess that possibility, Fig. 7 shows the correlation between peak Y-intercept for seven drugs tested in this study and peak breakpoint maintained by the same seven drugs in rhesus monkeys responding under a progressive-ratio schedule (Wee et al., 2005; Wang and Woolverton, 2007) . These data produced a statistically significant correlation (Pearson's r = 0.80, R 2 = 0.64, P < 0.05). Data for four other drugs could not be included in the correlation because either (a) they did not reliably maintain selfadministration under the progressive-ratio procedure so that a breakpoint could not be determined [(-)-MDMA, fenfluramine], or (b) they have not been tested in monkeys with the progressive-ratio procedure (phenmetrazine, PAL-287). However, phenmetrazine produced a relatively high peak Y-intercept in this study, and it functions as an effective reinforcer in self-administration assays in various species responding under various schedules of reinforcement (Wilson et al., 1971; Griffiths et al., 1976; Corwin et al., 1987) and also has verified abuse liability in humans (Craddock, 1976) . Conversely, (-)-MDMA, PAL-287, and fenfluramine produced relatively low peak Y-intercept values, and typically fail to maintain self-administration in animals (Tessel and Woods, 1975; Rothman et al., 2005; Wang and Woolverton, 2007) . Thus, the significant correlation presented in Fig. 7 , together with the qualitative examples provided above, suggests that peak Y-intercept values from rate-dependency plots may serve as a dependent measure in ICSS that is predictive of reinforcing efficacy in assays of drug self-administration. This possibility is further supported by recent studies with the m-opioid receptor agonist morphine (Altarifi and Negus, 2011) . In this study, the same Y-intercept metric of rate dependency also increased as a function of a variable (chronic opioid treatment) that is known to enhance other measures of m agonist abuse liability (e.g. breakpoints in progressive-ratio drug self-administration procedures in nonhuman primates). Additional work would be needed to assess the predictive validity of ICSS results for drug self-administration results across other classes of drugs or other conditions. Moreover, the present results raise the possibility that procedures other than ICSS (e.g. food-maintained responding under FI schedules) might offer alternative strategies for measuring rate dependence of drug effects and evaluating the relationship between rate dependence and reinforcing effects in assays of drug self-administration. Nonetheless, these results suggest one approach for using data from ICSS studies to predict outcomes of studies using drug self-administration or other procedures that contribute to abuse liability assessment.
The present results support the proposition that efficacy of drugs to produce abuse-related effects in preclinical assays can be distributed along a continuum, but the relationship of this theoretical continuum to metrics of actual drug abuse remains to be determined. Reinforcing drug effects assessed in drug self-administration procedures are considered sufficiently predictive of abuse liability that they are used to inform regulatory decisions on drug control (Ator and Griffiths, 2003; European Medicines Agency, 2006; Carter and Griffiths, 2009; Food and Drug Administration, 2010) , and graded drug effects in ICSS or drug self-administration assays bear at least a superficial correspondence to graded categories of drug scheduling by government entities such as the US Drug Enforcement Agency [e.g. amphetamine and methamphetamine as schedule II, fenfluramine as schedule IV (United States Department of Justice, Drug Enforcement Administration, Office of Diversion Control; http:// www.deadiversion.usdoj.gov/schedules/#list)]. However, regulatory and clinical metrics of abuse do not always correspond with one another or with preclinical metrics. In the class of monoamine releasers considered here, for example, methamphetamine maintained higher ICSS Y-intercepts and higher progressive-ratio breakpoints than (±)-MDMA (present study; Wang and Woolverton, 2007) . These data could be interpreted to suggest higher abuse liability for methamphetamine than for MDMA, and such a conclusion would agree with more frequent emergency room mentions and treatment episodes for methamphetamine than for MDMA in the USA (Substance Abuse and Mental Health Services Administration, 2009, 2010a). On the other hand, the prevalence of MDMA use exceeds that of methamphetamine use among persons aged 12 and older in the USA (Substance Abuse and Mental Health Services Administration, 2010b). Lastly, despite these sources of evidence for differential use and/or abuse of methamphetamine and MDMA, scheduling by the US Drug Enforcement Agency does not distinguish between the abuse liability of these drugs; both are considered to have high abuse liability, and differential placement in schedule II for methamphetamine and schedule I for MDMA reflects only the status of methamphetamine as an approved medication for clinical use. Taken together, these findings suggest that future research will be required to clarify the relationship between preclinical evidence for graded efficacies of abuse-related drug effects and different clinical manifestations of actual drug use and abuse.
Implications of rate dependence for mechanisms of drug effects on intracranial self-stimulation
In ICSS assays, responding is maintained by delivery of electrical brain stimulation, and effects of monoamine releasers and other drugs on ICSS are often interpreted as reflective of drug-induced changes in sensitivity to the reinforcing stimulus (Esposito et al., 1978; Wise, 1980) . From this perspective, drug effects on ICSS are considered to be dependent primarily on the magnitude of the reinforcing stimulus and on drug-induced changes in detection of that reinforcing stimulus. However, the observation of rate-dependent drug effects in the present study suggests that monoamine releaser effects on ICSS may be dependent instead on baseline rates of responding, and at least to some degree, independent of reinforcer magnitude. This conclusion resonates with earlier findings, for example, that amphetamine produced rate-dependent effects on rates of FI responding maintained by either food presentation or by stimulus-shock avoidance (e.g. Kelleher and Morse, 1968 ), suggesting the potential for independence of drug effects from reinforcer type. Moreover, indirect dopamine agonists can increase low rates of responding maintained in drug self-administration assays either by low cocaine doses or by vehicle, suggesting the potential for independence of drug effects from reinforcer magnitude (Panlilio et al., 1998; Barrett et al., 2004) . Lastly, recent studies with ICSS have also provided evidence to suggest that stimulant effects reflect processes other than enhanced sensitivity to the electrical stimulus (e.g. decreased sensitivity to the 'cost' of responding; Hernandez et al., 2010) . The results of the present study suggest that rate dependency may provide one source of reinforcer-independent factors that influence drug effects on ICSS.
